Date: 2017-12-19
Type of information: Research agreement
Compound: Locked Nucleic Acid (LNA) oligonucleotides
Company: Boehringer Ingelheim (Germany) Roche (Switzerland)
Therapeutic area: Autoimmune diseases - Inflammatory diseases - Digestive diseases
Type agreement: research - R&D - development
Action mechanism: oligonucleotide
Disease: inflammatory bowel diseases
Details:
- • On December 19, 2017, Boehringer Ingelheim announced a collaborative agreement with Roche, focusing on the discovery and development of orally available novel Locked Nucleic Acid (LNA) oligonucleotides for the treatment of inflammatory bowel diseases (IBDs). Together, Boehringer Ingelheim and Roche will leverage complementary expertise and innovative LNA technology to bring novel treatment approaches to IBD patients.
Under the agreement, Boehringer Ingelheim and Roche will collaborate on drug discovery and development, share clinical development costs and responsibility for the commercialization of potential products.
Financial terms:
Latest news:
Is general: Yes
